| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholera Vaccines | 19 | 2019 | 19 | 4.260 |
Why?
|
| Typhoid Fever | 17 | 2019 | 20 | 4.040 |
Why?
|
| Cholera | 21 | 2019 | 21 | 3.810 |
Why?
|
| Diarrhea | 20 | 2019 | 59 | 3.430 |
Why?
|
| Escherichia coli Infections | 15 | 2019 | 39 | 3.060 |
Why?
|
| Escherichia coli Vaccines | 9 | 2019 | 11 | 2.380 |
Why?
|
| Dysentery, Bacillary | 9 | 2019 | 12 | 2.060 |
Why?
|
| Enterotoxigenic Escherichia coli | 9 | 2019 | 15 | 1.850 |
Why?
|
| Child, Preschool | 48 | 2019 | 1354 | 1.680 |
Why?
|
| Shigella Vaccines | 5 | 2019 | 5 | 1.630 |
Why?
|
| Infant | 44 | 2019 | 1122 | 1.600 |
Why?
|
| Shigella | 6 | 2020 | 8 | 1.550 |
Why?
|
| Child | 47 | 2019 | 2613 | 1.500 |
Why?
|
| Vaccination | 10 | 2016 | 153 | 1.490 |
Why?
|
| Hepatitis E | 4 | 2018 | 6 | 1.460 |
Why?
|
| Salmonella Infections | 9 | 2018 | 10 | 1.440 |
Why?
|
| Developing Countries | 8 | 2019 | 60 | 1.310 |
Why?
|
| Adolescent | 43 | 2019 | 3799 | 1.280 |
Why?
|
| Disease Outbreaks | 7 | 2018 | 44 | 1.260 |
Why?
|
| Antibodies, Bacterial | 7 | 2019 | 37 | 1.200 |
Why?
|
| Mass Vaccination | 5 | 2016 | 9 | 1.130 |
Why?
|
| Humans | 92 | 2020 | 34474 | 1.070 |
Why?
|
| Influenza, Human | 7 | 2014 | 133 | 1.050 |
Why?
|
| Models, Theoretical | 3 | 2018 | 145 | 0.950 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 5 | 2019 | 6 | 0.940 |
Why?
|
| Immunity, Herd | 4 | 2019 | 6 | 0.880 |
Why?
|
| Fever | 7 | 2018 | 63 | 0.840 |
Why?
|
| Young Adult | 29 | 2019 | 2825 | 0.820 |
Why?
|
| Administration, Oral | 15 | 2019 | 212 | 0.820 |
Why?
|
| India | 13 | 2018 | 65 | 0.800 |
Why?
|
| Adult | 36 | 2020 | 10015 | 0.750 |
Why?
|
| Population Surveillance | 8 | 2014 | 133 | 0.740 |
Why?
|
| Vaccines, Conjugate | 5 | 2020 | 17 | 0.740 |
Why?
|
| Female | 51 | 2019 | 21490 | 0.720 |
Why?
|
| Bacterial Vaccines | 2 | 2012 | 8 | 0.710 |
Why?
|
| Paratyphoid Fever | 2 | 2019 | 3 | 0.690 |
Why?
|
| Salmonella | 3 | 2018 | 6 | 0.680 |
Why?
|
| Vibrio cholerae | 3 | 2015 | 3 | 0.670 |
Why?
|
| Shigella flexneri | 1 | 2020 | 3 | 0.670 |
Why?
|
| Male | 48 | 2019 | 20697 | 0.650 |
Why?
|
| Viral Vaccines | 2 | 2011 | 14 | 0.630 |
Why?
|
| Escherichia coli | 5 | 2014 | 92 | 0.630 |
Why?
|
| Salmonella typhi | 9 | 2018 | 11 | 0.620 |
Why?
|
| Vaccines, Inactivated | 10 | 2019 | 40 | 0.620 |
Why?
|
| Incidence | 12 | 2018 | 1288 | 0.600 |
Why?
|
| Sanitation | 1 | 2018 | 3 | 0.570 |
Why?
|
| Hygiene | 1 | 2018 | 13 | 0.570 |
Why?
|
| Mortality | 3 | 2019 | 127 | 0.560 |
Why?
|
| Rotavirus Infections | 4 | 2019 | 9 | 0.560 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 922 | 0.500 |
Why?
|
| Enteritis | 2 | 2019 | 5 | 0.500 |
Why?
|
| Encephalitis, Japanese | 3 | 2015 | 3 | 0.490 |
Why?
|
| Immunization, Secondary | 2 | 2016 | 14 | 0.490 |
Why?
|
| Rural Population | 8 | 2016 | 297 | 0.470 |
Why?
|
| Environmental Monitoring | 2 | 2013 | 29 | 0.460 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2012 | 12 | 0.450 |
Why?
|
| Water Supply | 1 | 2014 | 10 | 0.440 |
Why?
|
| Enteropathogenic Escherichia coli | 1 | 2014 | 2 | 0.440 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 51 | 0.440 |
Why?
|
| Diarrhea, Infantile | 1 | 2014 | 4 | 0.430 |
Why?
|
| Anti-Bacterial Agents | 9 | 2019 | 352 | 0.430 |
Why?
|
| Cause of Death | 2 | 2019 | 245 | 0.430 |
Why?
|
| Intestinal Perforation | 1 | 2014 | 10 | 0.420 |
Why?
|
| Salmonella enterica | 4 | 2016 | 6 | 0.390 |
Why?
|
| Infant, Newborn | 16 | 2019 | 730 | 0.390 |
Why?
|
| Africa South of the Sahara | 9 | 2019 | 22 | 0.390 |
Why?
|
| Length of Stay | 1 | 2014 | 335 | 0.380 |
Why?
|
| Egypt | 12 | 2014 | 13 | 0.370 |
Why?
|
| Neisseria meningitidis, Serogroup A | 1 | 2012 | 1 | 0.360 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 325 | 0.360 |
Why?
|
| Double-Blind Method | 8 | 2019 | 597 | 0.350 |
Why?
|
| Residence Characteristics | 2 | 2016 | 188 | 0.350 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 46 | 0.350 |
Why?
|
| Immunization | 3 | 2019 | 40 | 0.340 |
Why?
|
| Feces | 6 | 2019 | 43 | 0.320 |
Why?
|
| Cambodia | 8 | 2014 | 9 | 0.320 |
Why?
|
| Bacterial Infections | 2 | 2012 | 51 | 0.320 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2018 | 165 | 0.310 |
Why?
|
| Bacteremia | 3 | 2016 | 69 | 0.310 |
Why?
|
| Campylobacter Infections | 2 | 2008 | 5 | 0.300 |
Why?
|
| Growth Disorders | 2 | 2019 | 6 | 0.300 |
Why?
|
| Measles | 1 | 2009 | 4 | 0.300 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2008 | 7 | 0.290 |
Why?
|
| Tanzania | 9 | 2015 | 12 | 0.290 |
Why?
|
| Congresses as Topic | 2 | 2019 | 44 | 0.280 |
Why?
|
| Prevalence | 7 | 2019 | 1034 | 0.280 |
Why?
|
| Malaria | 4 | 2016 | 13 | 0.260 |
Why?
|
| Urban Population | 3 | 2017 | 97 | 0.260 |
Why?
|
| Middle Aged | 13 | 2019 | 12703 | 0.250 |
Why?
|
| Ciprofloxacin | 3 | 2016 | 13 | 0.250 |
Why?
|
| Cost of Illness | 3 | 2018 | 74 | 0.250 |
Why?
|
| Family Characteristics | 2 | 2017 | 39 | 0.240 |
Why?
|
| Bangladesh | 7 | 2019 | 8 | 0.240 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2019 | 22 | 0.240 |
Why?
|
| Risk Factors | 5 | 2018 | 4136 | 0.220 |
Why?
|
| Cohort Studies | 8 | 2019 | 1910 | 0.220 |
Why?
|
| Databases, Factual | 2 | 2016 | 378 | 0.210 |
Why?
|
| Japanese Encephalitis Vaccines | 2 | 2015 | 2 | 0.210 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 70 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 446 | 0.210 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2016 | 47 | 0.200 |
Why?
|
| Escherichia coli Proteins | 4 | 2019 | 35 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2016 | 177 | 0.190 |
Why?
|
| Immunization Schedule | 3 | 2019 | 27 | 0.180 |
Why?
|
| Nepal | 3 | 2014 | 11 | 0.170 |
Why?
|
| Africa | 3 | 2019 | 28 | 0.170 |
Why?
|
| Carbohydrates | 1 | 2020 | 11 | 0.170 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2019 | 81 | 0.170 |
Why?
|
| Antibody Formation | 2 | 2019 | 50 | 0.160 |
Why?
|
| Case-Control Studies | 5 | 2015 | 924 | 0.160 |
Why?
|
| Enterotoxins | 4 | 2019 | 9 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2020 | 214 | 0.160 |
Why?
|
| Gram-Negative Bacteria | 1 | 2019 | 10 | 0.160 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 14 | 0.150 |
Why?
|
| Immunoglobulin A | 5 | 2019 | 12 | 0.150 |
Why?
|
| Rotavirus Vaccines | 1 | 2019 | 6 | 0.150 |
Why?
|
| Geographic Information Systems | 1 | 2019 | 15 | 0.150 |
Why?
|
| Antigens, Bacterial | 1 | 2019 | 20 | 0.150 |
Why?
|
| Sensitivity and Specificity | 5 | 2012 | 612 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 25 | 0.150 |
Why?
|
| Cross-Sectional Studies | 5 | 2016 | 1607 | 0.150 |
Why?
|
| Immunoglobulin G | 5 | 2019 | 135 | 0.150 |
Why?
|
| Pregnant Women | 1 | 2018 | 6 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 197 | 0.140 |
Why?
|
| Hepatitis Antibodies | 1 | 2018 | 1 | 0.140 |
Why?
|
| Jaundice | 1 | 2018 | 5 | 0.140 |
Why?
|
| Treatment Outcome | 7 | 2015 | 3618 | 0.140 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1118 | 0.140 |
Why?
|
| Macaca mulatta | 1 | 2019 | 355 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 51 | 0.130 |
Why?
|
| Seroepidemiologic Studies | 2 | 2014 | 10 | 0.130 |
Why?
|
| Hepatitis E virus | 2 | 2014 | 3 | 0.130 |
Why?
|
| Drug Resistance, Multiple | 1 | 2017 | 9 | 0.130 |
Why?
|
| Vietnam | 2 | 2014 | 24 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 4150 | 0.130 |
Why?
|
| Washington | 1 | 2016 | 7 | 0.130 |
Why?
|
| Milk, Human | 1 | 2017 | 18 | 0.130 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2017 | 36 | 0.130 |
Why?
|
| Pregnancy | 3 | 2017 | 1069 | 0.130 |
Why?
|
| Geography | 2 | 2014 | 36 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2014 | 39 | 0.130 |
Why?
|
| Education | 1 | 2016 | 38 | 0.130 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 2 | 2014 | 3 | 0.120 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2017 | 70 | 0.120 |
Why?
|
| Endemic Diseases | 1 | 2016 | 4 | 0.120 |
Why?
|
| World Health Organization | 2 | 2014 | 17 | 0.120 |
Why?
|
| Uganda | 1 | 2016 | 9 | 0.120 |
Why?
|
| Indonesia | 1 | 2016 | 8 | 0.120 |
Why?
|
| Nigeria | 1 | 2016 | 17 | 0.120 |
Why?
|
| Poliovirus | 1 | 2016 | 3 | 0.120 |
Why?
|
| Antibody-Producing Cells | 1 | 2016 | 4 | 0.120 |
Why?
|
| Immunity, Mucosal | 1 | 2016 | 7 | 0.120 |
Why?
|
| Database Management Systems | 1 | 2016 | 12 | 0.120 |
Why?
|
| Bacterial Toxins | 3 | 2005 | 24 | 0.120 |
Why?
|
| Hospitalization | 2 | 2016 | 500 | 0.120 |
Why?
|
| Public Health | 2 | 2014 | 94 | 0.120 |
Why?
|
| Aged | 6 | 2016 | 10998 | 0.120 |
Why?
|
| Salmonella paratyphi A | 2 | 2013 | 2 | 0.120 |
Why?
|
| Mice | 2 | 2019 | 2691 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 79 | 0.110 |
Why?
|
| Haemophilus Vaccines | 1 | 2015 | 1 | 0.110 |
Why?
|
| Bacterial Capsules | 1 | 2015 | 5 | 0.110 |
Why?
|
| Haemophilus Infections | 1 | 2015 | 8 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2019 | 1506 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 801 | 0.110 |
Why?
|
| Research Design | 2 | 2015 | 337 | 0.110 |
Why?
|
| Genotype | 2 | 2014 | 743 | 0.110 |
Why?
|
| Health Expenditures | 1 | 2015 | 71 | 0.110 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 16 | 0.110 |
Why?
|
| Phenotype | 2 | 2014 | 656 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 281 | 0.110 |
Why?
|
| Animals | 5 | 2019 | 8544 | 0.100 |
Why?
|
| Salmonella Vaccines | 1 | 2013 | 1 | 0.100 |
Why?
|
| Internationality | 1 | 2013 | 24 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2014 | 85 | 0.100 |
Why?
|
| Population Density | 1 | 2013 | 9 | 0.100 |
Why?
|
| Educational Status | 1 | 2014 | 185 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 565 | 0.100 |
Why?
|
| Republic of Korea | 1 | 2012 | 12 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 193 | 0.090 |
Why?
|
| Niger | 1 | 2012 | 1 | 0.090 |
Why?
|
| Dengue | 1 | 2012 | 5 | 0.090 |
Why?
|
| Computers, Handheld | 1 | 2012 | 15 | 0.090 |
Why?
|
| Sex Factors | 1 | 2014 | 707 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 174 | 0.090 |
Why?
|
| Community-Acquired Infections | 1 | 2012 | 33 | 0.090 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2011 | 24 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 819 | 0.090 |
Why?
|
| Data Collection | 1 | 2012 | 191 | 0.090 |
Why?
|
| Vibrio cholerae O1 | 3 | 2015 | 3 | 0.080 |
Why?
|
| Rotavirus | 1 | 2010 | 3 | 0.080 |
Why?
|
| Orthomyxoviridae | 1 | 2010 | 15 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 2 | 2019 | 63 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 260 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 364 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2009 | 11 | 0.080 |
Why?
|
| Asia | 3 | 2013 | 19 | 0.070 |
Why?
|
| Gangliosides | 1 | 2008 | 7 | 0.070 |
Why?
|
| Indian Ocean Islands | 3 | 2013 | 3 | 0.070 |
Why?
|
| Cluster Analysis | 3 | 2013 | 128 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2017 | 2461 | 0.070 |
Why?
|
| Azithromycin | 2 | 2004 | 16 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2014 | 3812 | 0.060 |
Why?
|
| Hospitals | 3 | 2012 | 105 | 0.060 |
Why?
|
| Survival Rate | 1 | 2009 | 925 | 0.060 |
Why?
|
| Vaccines, Subunit | 2 | 2016 | 4 | 0.060 |
Why?
|
| Ghana | 2 | 2016 | 24 | 0.060 |
Why?
|
| Seasons | 1 | 2006 | 94 | 0.060 |
Why?
|
| Cryptosporidiosis | 1 | 2005 | 2 | 0.060 |
Why?
|
| Cryptosporidium parvum | 1 | 2005 | 2 | 0.060 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2005 | 1 | 0.060 |
Why?
|
| Tuberculoma, Intracranial | 1 | 2005 | 1 | 0.060 |
Why?
|
| Granuloma | 1 | 2005 | 14 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2005 | 31 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2005 | 64 | 0.050 |
Why?
|
| Placebos | 2 | 2015 | 69 | 0.050 |
Why?
|
| Biomedical Research | 2 | 2016 | 186 | 0.050 |
Why?
|
| Campylobacter coli | 1 | 2003 | 2 | 0.050 |
Why?
|
| Campylobacter jejuni | 1 | 2003 | 3 | 0.050 |
Why?
|
| Probability | 3 | 2012 | 168 | 0.050 |
Why?
|
| Age Factors | 2 | 2016 | 1261 | 0.050 |
Why?
|
| Cholera Toxin | 1 | 2002 | 6 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 803 | 0.050 |
Why?
|
| Serotyping | 2 | 2016 | 19 | 0.040 |
Why?
|
| Bacteria | 2 | 2012 | 56 | 0.040 |
Why?
|
| Prognosis | 3 | 2016 | 1603 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 2019 | 10 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2019 | 13 | 0.040 |
Why?
|
| Shigella sonnei | 1 | 2019 | 1 | 0.040 |
Why?
|
| Vaccines, Attenuated | 1 | 2019 | 12 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2019 | 19 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 35 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 17 | 0.040 |
Why?
|
| Electrochemical Techniques | 1 | 2018 | 26 | 0.040 |
Why?
|
| Age Distribution | 2 | 2012 | 211 | 0.040 |
Why?
|
| Vaccines, Combined | 1 | 2017 | 3 | 0.030 |
Why?
|
| Lactation | 1 | 2017 | 19 | 0.030 |
Why?
|
| Guinea-Bissau | 1 | 2016 | 1 | 0.030 |
Why?
|
| Senegal | 1 | 2016 | 1 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2016 | 21 | 0.030 |
Why?
|
| Clinical Audit | 1 | 2016 | 1 | 0.030 |
Why?
|
| Poliomyelitis | 1 | 2016 | 3 | 0.030 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2016 | 3 | 0.030 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2016 | 3 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 23 | 0.030 |
Why?
|
| Weights and Measures | 1 | 2015 | 3 | 0.030 |
Why?
|
| Anthropometry | 1 | 2016 | 88 | 0.030 |
Why?
|
| Ethiopia | 1 | 2015 | 1 | 0.030 |
Why?
|
| Vibrio cholerae O139 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Outpatients | 1 | 2015 | 61 | 0.030 |
Why?
|
| Democratic People's Republic of Korea | 1 | 2015 | 1 | 0.030 |
Why?
|
| Inpatients | 1 | 2015 | 88 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 508 | 0.030 |
Why?
|
| Fimbriae Proteins | 2 | 2005 | 5 | 0.030 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2014 | 4 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2014 | 63 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2014 | 40 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2014 | 76 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 953 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2013 | 38 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2013 | 5 | 0.020 |
Why?
|
| Agglutination Tests | 1 | 2012 | 3 | 0.020 |
Why?
|
| Technology, Pharmaceutical | 1 | 2012 | 3 | 0.020 |
Why?
|
| Immunization Programs | 1 | 2012 | 30 | 0.020 |
Why?
|
| Communication | 1 | 2014 | 144 | 0.020 |
Why?
|
| Hantavirus | 1 | 2012 | 1 | 0.020 |
Why?
|
| Orientia tsutsugamushi | 1 | 2012 | 1 | 0.020 |
Why?
|
| Rickettsia | 1 | 2012 | 3 | 0.020 |
Why?
|
| Health Policy | 1 | 2012 | 96 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 325 | 0.020 |
Why?
|
| Information Storage and Retrieval | 1 | 2012 | 28 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2012 | 33 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2012 | 38 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 583 | 0.020 |
Why?
|
| Decision Making | 1 | 2014 | 203 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 426 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 276 | 0.020 |
Why?
|
| Pharyngitis | 1 | 2010 | 10 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 323 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 49 | 0.020 |
Why?
|
| Cough | 1 | 2010 | 21 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2013 | 237 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 2352 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 934 | 0.020 |
Why?
|
| Brain | 1 | 2012 | 1031 | 0.010 |
Why?
|
| Virulence Factors | 1 | 2005 | 13 | 0.010 |
Why?
|
| Virulence | 1 | 2004 | 22 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 194 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2005 | 100 | 0.010 |
Why?
|
| Erythromycin | 1 | 2003 | 8 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 703 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 808 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2004 | 230 | 0.010 |
Why?
|
| Pediatrics | 1 | 2003 | 167 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 755 | 0.010 |
Why?
|